• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Almac Group

    PCI Pharma Services

    Emergent BioSolutions

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    PCI Pharma Services

    test company saurabh

    Reed-Lane

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CAR-T Cell Therapy in Clinical Trials

    The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus

    CAR-T Cell Therapy in Clinical Trials
    Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD06.04.20
    Global drug developers in partnership with leading scientists have sharpened focus on advancing the development of CAR-T therapies, expanding applications and improving key logistics of this evolving therapeutic field. In turn, we are seeing three major themes emerging in global discussions about CAR-T in 2020.

    Seeking more sophisticated CAR engineering for solid tumors
    CAR-T therapeutics continue to drive the paradigm shift of therapies for patients who are at the end of treatment options for hematological malignancies ranging from palliative to potentially curative. Antigens for CAR-T in liquid tumors are fairly well defined compared to solid tumors, which are much less defined. Therein lies the clinical challenge of translating liquid tumor experience to solid tumor applications. The data supports the need for more sophisticated and scientific engineering of the CAR.

    Global medical professionals acknowledge the broad potential of CAR-T cell therapy. To date, it has been validated in relapsed and refractory B-ALL malignancies, while the current clinical responses in solid tumors have been sporadic. Solid tumors are a challenge for multiple reasons including:
    • Lack of antigen specificity;
    • Poor trafficking and expansion;
    • Hostile immunosuppressive microenvironment;
    • Tumor escape and relapse;
    • Toxicity of CARs; and
    • Time-consuming and expensive manufacturing of CAR-T cells.
    Given the limitations of current CAR-T cell therapy, sophisticated strategies are under investigation to overcome them. They include:
    • Targeting multiple tumor antigens to lessen antigen escape;
    • Harnessing immune checkpoint inhibitors to increase effector response;
    • Using next-generation CAR-T cell engineering to overcome antigen heterogeneity, to mitigate T-cell exhaustion and to prevent suppression by the tumor microenvironment; and
    • Regional infusion of CAR-T cells for direct effect.
    In particular, innovative CAR design and logic-gated approaches allow for exploiting the full therapeutic potential of CAR-T cells and enabling treatment of a broader range of cancer patients in the near future. Apart from autologous T-cells as the major source used at present, allogeneic cells including stem cell-derived, “off-the-shelf” T-cells may play an important role in the future.

    In addition, genome-editing technology is being explored as a strategy to advance the scientific engineering of the CAR. Compared with conventional CAR-T cells, CRISPR/Cas9-edited CAR-T cells have shown an enhanced potency, delayed differentiation and exhaustion – all findings that highlight genome-editing technology as a promising approach for additional changes and improvements to the infused CAR-T cells. In addition to genome-editing technology, other therapeutic measures—including chemotherapies, radiation, immune checkpoint blockade antibodies and cytokine treatment—also may be combined with CAR-T cell therapy to broaden the application and enhance the efficacy for individual cancer elimination. Despite progress in managing severe cytokine release and neurotoxicity, the mechanisms at hand are poorly understood. On that, drug developers and the global medical community agree that further research in CAR-T cell therapy for treating solid cancers deserves significantly more attention.

    Efficient management of logistics in the clinic
    Managing patients and sample procurement during the critical “vein-to-vein” time in studies for autologous CAR-T therapies is complex and challenging. In addition to these studies having patients who are significantly ill, the processes in place require multiple parties and many handoff processes for study samples. Logistics in CAR-T studies require keen oversight, management of complex processes and an understanding of patient profiles and pathways. This is a true multidisciplinary approach in which leading academic teaching hospitals supporting this work are exploring more refined and innovative processes. Clinical research organizations (CROs) have a significant role to play here, not only in training, but also in oversight of the logistics process. There continues to be critical importance placed on comprehensive training at sites – a broader look beyond training for nurses, physicians and pharmacists. We are seeing an increasing need to engage and train administrative staff who are responsible for moving patients from one department/facility/site to another.

    For example, CROs deploy clinical logistics coordinators who work closely with sites and sponsors to oversee and track patients and their samples—a closed loop approach to prescreening and slot allocation to apheresis through manufacturing and back to the patient for infusion.

    Advances in development of “off-the-shelf” allogeneic products will help reduce manufacturing and thus logistical challenges. Furthermore, they also may provide a more functional, potent product for malignancies such as CLL, where T-cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process.

    Regulatory and health technology assessments (HTA) strategies
    As use cases for CAR-T increase, there are open requests from both regulators like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and organizations such as the National Institute for Health (NIH) and Care Excellence and Institute for Clinical and Economic Review for manufacturers to engage early on assessment and acceptance requirements for advanced therapies. These organizations are experiencing a steep learning curve as they address this initial wave of advanced therapies that have transformative or even curative potential.

    Given the novelty and complexity of CAR-T and other cell and gene therapies, including the need to demonstrate transformative and longer-term effect, it is critical to plan for regulatory and market access requirements early in development. Many of these therapies have been launched with single-arm results and all of them require a registry. Optimizing the evidence synergies between pivotal trial design, real-world evidence and the registry is critical to ensuring acceptance and uptake for these therapies. This includes utilizing solutions like synthetic control arms to address the need for comparative evidence and how a registry can be a tool to support risk sharing and novel payment strategies in some markets.

    Understanding regulatory and HTA/payer requirements early, planning for changing evidence development approaches for transformative therapies and approaching development in an integrated fashion are key ingredients to an efficient and comprehensive strategy for success. This is underscored by the uptick in emphasis on integrated scientific advice that we are seeing in the marketplace.

    Impact of COVID-19
    The COVID-19 pandemic has caused significant constraints globally in the delivery of cellular therapy in order to ensure patient and site safety. This includes partial closures of outpatient clinics, decreased infusion suite capacity and a resultant decrease in clinical staff. It is acknowledged that CAR-T cell therapy requires intensive and valuable resources necessitating significant logistical planning.

    In preparation for this surge of virally infected patients, hospitals across the world have instituted measures to defer multiple patient care interventions, including such treatments as autologous stem cell transplantation. Given that CAR-T cells are potentially curative for patients with an otherwise dismal prognosis, outpatient CAR-T administration should be considered, when feasible, to reduce inpatient health care utilization. This may not be practical to uniformly institute in all centers and must address available resources and the viral burden in the surrounding community. Consequently, inpatient admission may be more appropriate at certain centers.

    Looking beyond 2020
    Cell and gene therapeutics such as CAR-T have shifted the paradigm of care from palliative to potentially curative. Throughout 2020 and alongside global colleagues, we will continue to work with partners to explore increased sophistication and scientific engineering of the CAR, improve logistics throughout the life cycle of development, and keep patient experiences and needs at the forefront of global work to deliver life-changing therapeutics to those who need them most. 
    Related Searches
    • Biologics, Proteins, Vaccines

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20


    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20

    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20


    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20

    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20


    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Arkema Reports Full-year 2020 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Madison Reed Raises $52 Million in Financing Round
    Happi

    Latest Breaking News From Happi

    ACI Unveils New Online Resources
    Sales More Than Double at Madison Reed
    PBA Opposes House Bill 2325 in West Virginia
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    S-OneLP adds to growing team
    Avery Dennison expands automotive portfolio
    Amberley Labels turns to Kurz for embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    H&V Announces Price Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login